[Experience in heptral treatment of diffuse liver diseases].
OBJECTIVE
Heptral trial in alcoholic, drug and viral diseases of the liver.


METHODS
67 patients with chronic diffuse liver diseases were treated with heptral. The examination covered AlAt, AP, HHTP, bilirubin, cholesterol, CT of the liver, esophagogastroduodenoscopy. Heptral was given by two steps: 14 days of intravenous drops (800 mg/day) followed by 14 days of oral use (2 tablets, 400 mg each) before meal at 8 a.m. and 2 p.m.


RESULTS
In alcoholic disease of the liver, heptral relieved depression, reduced AlAT, AP, HHTP, bilirubin, density of the liver. The addition of heptral to interferon-alpha-2 treatment of chronic hepatitis C corrected intrahepatic cholestasis. In drug-induced liver damage heptral promoted normalization of the hepatic tests, improved general condition of the patients.


CONCLUSIONS
Heptral is effective in patients with alcoholic and drug liver lesions, chronic hepatitis C.
Gorbakov
V V
VV
Galik
V P
VP
Kirillov
S M
SM
D000293:Adolescent; D000328:Adult; D000368:Aged; D001707:Biopsy, Needle; D016145:Endoscopy, Digestive System; D005500:Follow-Up Studies; D019694:Hepatitis B, Chronic / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008104:Liver Cirrhosis, Alcoholic / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D012436:S-Adenosylmethionine / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D012436:S-Adenosylmethionine
Opyt primeneniia geptrala v lechenii diffuznykh zabolevaniĭ pecheni.